In recent years, synbrAIn has made significant strides in the field of Digital Healthcare, developing numerous AI and machine learning-driven solutions to support medical diagnostics.
Within this framework, a strong collaboration has emerged with EMME ESSE, a company with over 40 years of experience in the healthcare sector, specializing in bio-imaging. EMME ESSE provides high-tech diagnostic equipment, clinical data and image management solutions, and systems for process digitalization and dematerialization.
On May 16, 2022, synbrAIn and EMME ESSE solidified their partnership through a capital increase subscription, making Emme Esse a shareholder with a 20% stake in synbrAIn.
A Crucial Step for Growth
EMME ESSE’s participation marks a key milestone in synbrAIn’s growth, accelerating product development in Digital Healthcare applications. Additionally, EMME ESSE’s extensive direct and indirect commercial network—including new, significant international expansions—represents a strategic advantage.
The fields of Medical Imaging and Healthcare are undergoing a profound digital revolution. The future of healthcare is being shaped by the synergy of IT, medical, and technological expertise, leading to the development of digital tools that enhance disease monitoring, prevention, and treatment, ultimately improving healthcare services for both patients and physicians.
Once again, EMME ESSE and synbrAIn join forces to play an active role in this groundbreaking transformation.
A Long-Standing Partnership Leading to Investment
The collaboration between EMME ESSE and synbrAIn began in 2020, with both companies working together on the development and launch of the AI-powered platform MS humanAId.
Additionally, Elisa Mattavelli, CEO of EMME ESSE, has joined synbrAIn’s Board of Directors. Commenting on this new partnership, she stated:
“In recent years, EMME ESSE has been investing heavily in the development of proprietary solutions. Our AI platform MS humanAId, along with the PHYSICO suite, represent our top strategic growth areas for the future. Artificial Intelligence is becoming a crucial component of our corporate development plans. Through our investment in synbrAIn, EMME ESSE will take on an even more significant role in shaping the future of this market.”
Roberto Pagani, CEO of synbrAIn, added:
“Having EMME ESSE as a new shareholder will accelerate our research and development efforts, with a strong focus on Digital Healthcare applications.”
